Edwin M Posadas

Edwin M Posadas

UNVERIFIED PROFILE

Are you Edwin M Posadas?   Register this Author

Register author
Edwin M Posadas

Edwin M Posadas

Publications by authors named "Edwin M Posadas"

Are you Edwin M Posadas?   Register this Author

68Publications

1345Reads

26Profile Views

Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous.

J Clin Oncol 2019 Aug 20;37(23):1987-1989. Epub 2019 Jun 20.

1Cedars-Sinai Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00639DOI Listing
August 2019

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Clin Genitourin Cancer 2019 Jun 15;17(3):e454-e460. Epub 2019 Jan 15.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.004DOI Listing
June 2019

Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.

Expert Rev Anticancer Ther 2019 Mar 4;19(3):259-271. Epub 2019 Feb 4.

a Department of Medicine, Division of Hematology and Oncology , Cedars-Sinai Medical Center , Los Angeles , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1573678DOI Listing
March 2019

Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential.

Cancer Res 2018 11 28;78(21):6086-6097. Epub 2018 Aug 28.

Division of Cancer Biology and Therapeutics, Department of Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0608DOI Listing
November 2018

Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells.

Cancer Med 2018 09 9;7(9):4639-4649. Epub 2018 Aug 9.

Urologic Oncology Program/Uro-Oncology Research Laboratories, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143932PMC
September 2018

Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer.

Am J Clin Exp Urol 2018 1;6(2):43-54. Epub 2018 Apr 1.

Urologic Oncology Program & Uro-Oncology Laboratories, Samuel Oschin Comprehensive Cancer InstituteLos Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5902722PMC
April 2018

Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate.

J Med Chem 2018 03 27;61(5):2052-2061. Epub 2018 Feb 27.

Division of Biomedical Sciences, School of Medicine , University of California, Riverside , 900 University Avenue , Riverside , California 92521 , United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01837
Publisher Site
http://dx.doi.org/10.1021/acs.jmedchem.7b01837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907794PMC
March 2018

NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

Adv Drug Deliv Rev 2018 02 15;125:78-93. Epub 2018 Mar 15.

Department of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2018.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993593PMC
February 2018

Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells.

Theranostics 2016 15;6(9):1425-39. Epub 2016 Jun 15.

2. Department of Molecular and Medical Pharmacology, California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, Los Angeles, California, USA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.15359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924510PMC
October 2017

In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.

Eur Urol Focus 2017 10 29;3(4-5):480-486. Epub 2016 Aug 29.

Urology Section, Veterans Affairs Medical Center, Durham, NC, USA; Department of Surgery, Division of Urology and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.08.007DOI Listing
October 2017

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Oncotarget 2017 Oct 23;8(50):87891-87902. Epub 2017 Sep 23.

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675680PMC
October 2017

Targeted therapies for renal cell carcinoma.

Nat Rev Nephrol 2017 Aug 10;13(8):496-511. Epub 2017 Jul 10.

Urologic Oncology Program &Translational Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Department of Pharmacy Services, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneph.2017.82DOI Listing
August 2017

MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.

Cancer Res 2017 05 15;77(9):2306-2317. Epub 2017 Feb 15.

Division of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-2942DOI Listing
May 2017

MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions.

Cancer Cell 2017 03;31(3):368-382

Uro-Oncology Research Program, Samuel Oschin Comprehensive Cancer Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.02.003DOI Listing
March 2017

Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Drugs 2017 Jan;77(1):17-28

Urologic Oncology Program and Translational Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-016-0665-1DOI Listing
January 2017

Circulating tumor cells in prostate cancer: beyond enumeration.

Clin Adv Hematol Oncol 2017 Jan;15(1):63-73

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
January 2017

Biology and therapy of urological cancer metastasis.

Asian J Urol 2016 Oct 23;3(4):167-169. Epub 2016 Sep 23.

Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajur.2016.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730865PMC
October 2016

Applications of circulating tumor cells for prostate cancer.

Asian J Urol 2016 Oct 14;3(4):254-259. Epub 2016 Sep 14.

Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajur.2016.09.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730870PMC
October 2016

Third-Line Treatment Options for Kidney Cancer.

Oncology (Williston Park) 2016 09;30(9):813-5

View Article

Download full-text PDF

Source
September 2016

Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy.

J Oncol Pract 2016 05;12(5):424-5

Cedars-Sinai Medical Center, Los Angeles, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.012393DOI Listing
May 2016

miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer.

Clin Cancer Res 2014 Dec 16;20(24):6559-69. Epub 2014 Oct 16.

Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1784DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710473PMC
December 2014

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.

PLoS One 2014 14;9(2):e88967. Epub 2014 Feb 14.

Uro-Oncolgy Research Laboratories, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angles, California, United States of America ; Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angles, California, United States of America ; Division of Hematology Oncology-Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0088967PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925210PMC
October 2014

Kidney cancer: progress and controversies in neoadjuvant therapy.

Nat Rev Urol 2014 May 22;11(5):254-5. Epub 2014 Apr 22.

Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2014.89DOI Listing
May 2014

NanoVelcro Chip for CTC enumeration in prostate cancer patients.

Methods 2013 Dec 29;64(2):144-52. Epub 2013 Jun 29.

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Urologic Oncology Program & Uro-Oncology Research Program, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymeth.2013.06.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834112PMC
December 2013

Targeting angiogenesis in renal cell carcinoma.

Expert Opin Pharmacother 2013 Nov 28;14(16):2221-36. Epub 2013 Aug 28.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Urologic Oncology Program , 8700 Beverly Blvd, Los Angeles, CA 90048 , USA +1 310 423 7600 ; +1 310 659 3928 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2013.832202DOI Listing
November 2013

High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing.

Adv Mater 2013 Jun 26;25(21):2897-902. Epub 2013 Mar 26.

Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Science, Beiyi Street 2#, Zhongguancun, Beijing, 100190, P. R. China; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging (CIMI), California NanoSystems Institute (CNSI), University of California at Los Angeles, 570 Westwood Plaza, Build 114, Los Angeles, California 90095-1770, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adma.201205237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875622PMC
June 2013

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.

Cancer Chemother Pharmacol 2013 Apr 13;71(4):883-92. Epub 2013 Jan 13.

Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1M45, Baltimore, MD 21231-1000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2079-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609871PMC
April 2013

Understanding the role of MET kinase in cancer therapy.

J Clin Oncol 2013 Jan 3;31(2):169-70. Epub 2012 Dec 3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.7738DOI Listing
January 2013

Systemic therapy in renal cell carcinoma: advancing paradigms.

Oncology (Williston Park) 2012 Mar;26(3):290-301

View Article

Download full-text PDF

Source
March 2012

Future perspectives of prostate cancer therapy.

Transl Androl Urol 2012 Jan;1(1):19-32

Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2223-4683.2012.01.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389805PMC
January 2012

A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.

Am J Clin Oncol 2011 Apr;34(2):150-4

Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0b013e3181d6b2feDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644601PMC
April 2011

Editorial comment.

Urology 2011 Jan;77(1):165-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2010.05.008DOI Listing
January 2011

Fyn: a novel molecular target in cancer.

Cancer 2010 Apr;116(7):1629-37

Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24879DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847065PMC
April 2010

Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy.

Nat Rev Urol 2010 Feb;7(2):110-4

Section of Hematology/Oncology and Department of Medicine, The University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2009.255DOI Listing
February 2010

Kinase inhibitors in prostate cancer.

Anticancer Agents Med Chem 2009 Dec;9(10):1089-104

Department of Pharmaceutical Services, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
December 2009

Pazopanib: therapeutic developments.

Expert Opin Pharmacother 2009 Dec;10(18):3091-102

University of Chicago, Department of Pharmaceutical Services, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656560903436493DOI Listing
December 2009

Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.

Clin Genitourin Cancer 2009 Jan;7(1):39-42

Department of Medicine, Section of Hematology/Oncology, University of Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S155876731170013
Publisher Site
http://dx.doi.org/10.3816/CGC.2009.n.007DOI Listing
January 2009

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

J Clin Oncol 2008 Aug;26(22):3709-14

Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.10.8332DOI Listing
August 2008

A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.

Cancer Biol Ther 2007 Apr;6(4):490-3

University of Chicago Phase II Consortium, Section of Hematology/Oncology, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.6.4.3831DOI Listing
April 2007

A phase II study of perifosine in androgen independent prostate cancer.

Cancer Biol Ther 2005 Oct 1;4(10):1133-7. Epub 2005 Oct 1.

Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.4.10.2064DOI Listing
October 2005

Management of patients with metastatic cancer of unknown primary.

Curr Probl Surg 2005 Jan;42(1):12-66

Pathology, State University of New York-Brooklyn, Brooklyn, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1067/j.cpsurg.2004.10.002DOI Listing
January 2005

Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.

Curr Opin Oncol 2004 Sep;16(5):478-84

Laboratory of Pathology, National Cancer Institute and NCI/FDA Clinical Proteomics Program Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001622-200409000-00012DOI Listing
September 2004

The emerging role of bisphosphonates in prostate cancer.

Am J Ther 2004 Jan-Feb;11(1):60-73

Medical Oncology Clinical Research Unit, Laboratory of Tumor Immunology and Biology, Center for Cancer Research National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC 1750, Building 10, Room 5B52, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
May 2004

Approaches to inhibit invasiveness and metastasis in prostate cancer.

Clin Prostate Cancer 2002 Sep;1(2):125

National Cancer Institute National Institutes of Health Bethesda, MD, USA.

View Article

Download full-text PDF

Source
September 2002